Protagonist Therapeutics (United States)

Recent papers from Protagonist Therapeutics (United States)

1. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care TherapyJournal of Clinical Oncology · 2026
2. Symptoms and life impact of polycythemia vera (PV): Results from a qualitative patient interview study.Journal of Clinical Oncology · 2026
3. Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study.2026
4. Risk of Thromboembolic Events in Patients with Polycythemia Vera: A Real-World Observational StudyClinical Lymphoma Myeloma & Leukemia · 2026
5. Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia veraLeukemia Research · 2025
6. Developmentof Lipopeptides as Orthoflavivirin Inhibitorswith Low Micromolar Broad-Spectrum Antiorthoflaviviral ActivityJournal of Medicinal Chemistry · 2025
7. Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy ParticipantsClinical Therapeutics · 2025
8. An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims databaseExpert Review of Hematology · 2025
9. Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits SignalingDermatology and Therapy · 2025
10. Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).Journal of Clinical Oncology · 2025
11. Multiple‐Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy SubjectsClinical Pharmacology in Drug Development · 2025
12. American Society of Hematology: building a comprehensive minority recruitment and retention professional programBlood Advances · 2024
13. Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy VolunteersDrugs in R&D · 2024
14. Quality of Life in Patients with Malignant Wounds Treated at a Wound Care Clinic2024
15. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humansScientific Reports · 2024
16. NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024Journal of the National Comprehensive Cancer Network · 2024
17. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).Journal of Clinical Oncology · 2024
18. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG‐300), a hepcidin mimetic, in healthy volunteers: A double‐blind first‐in‐human studyEuropean Journal Of Haematology · 2024
19. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and PhysiciansClinical Lymphoma Myeloma & Leukemia · 2024
20. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective CohortsCellular and Molecular Gastroenterology and Hepatology · 2024